Literature DB >> 6159514

Epstein-Barr-virus-induced lymphoproliferative disorder converting to fatal Burkitt-like lymphoma in a boy with interferon-inducible chromosomal defect.

K Thestrup-Pedersen, V Esmann, S Bisballe, J R Jensen, G Pallesen, J Hastrup, M Madsen, K Thorling, M Grazia-Masucci, A K Saemundsen, I Ernberg.   

Abstract

A 6-year-old boy presenting with swelling of cervical and axillary lymph-nodes was diagnosed as having an Epstein-Barr virus infection because of EBV-nuclear-antigen-positive B-lymphocytes in blood and lymph nodes and high antibody titres to EBV antigens. The natural killer activity of blood-lymphocytes was low, and so was the percentage of T-lymphocytes with Fc receptors for IgG (T-gamma cells). Chromosomal studies revealed a defect in the long arms of one of the chromosomes in pair no. 16 (16q22). The defect only appeared after addition of interferon to the lymphocyte cultures and preferentially in T-gamma lymphocytes. The disease progressed despite attempts to restore the patient's immune reactivity by interferon, transfer factor, and blood transfusions. Necropsy showed that the severe hyperplasia of lymph nodes found during life had become a Burkitt-like lymphoma. The possible connection between an interferon-induced chromosomal defect (break at 16q22) and reduced level of natural killer activity, reduced T-gamma lymphocytes, and proliferation of EBV-positive B-lymphocytes is discussed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6159514     DOI: 10.1016/s0140-6736(80)92156-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  11 in total

1.  Different inducibility and possible significance of several concomitant "fragile sites" in two brothers.

Authors:  F Shabtai; J Orlin; J Hart; I Halbrecht; D Klar; J Friedman
Journal:  Hum Genet       Date:  1986-09       Impact factor: 4.132

2.  Immune function in chronic active Epstein-Barr virus infection.

Authors:  R Kibler; D O Lucas; M J Hicks; B T Poulos; J F Jones
Journal:  J Clin Immunol       Date:  1985-01       Impact factor: 8.317

3.  The fragile site (16) (q22). I. Induction by AT-specific DNA-ligands and population frequency.

Authors:  M Schmid; W Feichtinger; A Jessberger; J Köhler; R Lange
Journal:  Hum Genet       Date:  1986-09       Impact factor: 4.132

4.  Alpha-interferon and fragility at 16q22. A study on 15 selected controls and 146 selected patients.

Authors:  F Shabtai; J Orlyn; J Hart; S Bichacho; I Halbrecht
Journal:  Hum Genet       Date:  1987-01       Impact factor: 4.132

5.  Familial fragility on chromosome 16 (fra 16q22) enhanced by both interferon and Distamycin A.

Authors:  F Shabtai; D Klar; S Bichacho; J Hart; I Halbrecht
Journal:  Hum Genet       Date:  1983       Impact factor: 4.132

Review 6.  Depressed immunity and the development of cancer.

Authors:  I Penn
Journal:  Clin Exp Immunol       Date:  1981-12       Impact factor: 4.330

7.  Fragile sites and structural rearrangements in cancer.

Authors:  M De Braekeleer; B Smith; C C Lin
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

Review 8.  Human monoclonal antibodies.

Authors:  S P Cole; B G Campling; T Atlaw; D Kozbor; J C Roder
Journal:  Mol Cell Biochem       Date:  1984-06       Impact factor: 3.396

9.  The use of distamycin A in human lymphocyte cultures.

Authors:  M Schmid; D A Hungerford; A Poppen; W Engel
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

10.  A prospective study on infectious mononucleosis in childhood--symptoms, serology, Epstein-Barr-Virus specific leukocyte migration inhibition.

Authors:  L Timár; J Budai; M Koller
Journal:  Infection       Date:  1982       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.